The Journal of Heart and Lung Transplantation
International Society for Heart and Lung Transplantation.

Role of TGF-β1 +869T>C polymorphism in renal dysfunction one year after heart transplantation

Published:September 14, 2022DOI:


      Chronic kidney disease is a major complication after heart transplantation with wide inter-individual variability. Calcineurin inhibitor nephrotoxicity, mediated by transforming growth factor-beta1 (TGF-β1), is an important contributing factor. Our objective was to evaluate the association between TGF-β1 polymorphisms and renal dysfunction 1-year after heart transplantation.


      Single-center observational study that included patients who received a first heart transplant between 1990-2013. According to the 1-year eGFR decline, patients were classified as “Stable” (decrease in eGFR<10% or eGFR>60 ml/min/1.73m2) or “Progressors” (decrease in eGFR>10% and eGFR<60 ml/min/1.73m2). “Progressors” were then subdivided by the degree of eGFR decrease in “Mild progressors” (10-30%) or “Rapid progressors” (>30%). The association between TGF-β1 +869T>C polymorphism and other risk factors with the eGFR outcome was analysed.


      A total of 355 patients (78% male; 50.7 ± 11.8 years) were included. According to the 1-year eGFR decline, 220 patients (62%) were classified as “Stable” and 135 (38%) as “Progressors”. TGF-β1+869CC genotype was more prevalent in “Stable” vs “Progressors” group (20% vs 8%, p = 0.009). In the multivariate analysis, female sex (p 0.02) and eGFR<60 ml/min/1.73 m2 at first month post-heart transplant (p = 0.004) remained as risk factors of eGFR decline, and TGF-β1 + 869CC genotype (p = 0.001) and renal dysfunction pre-heart transplant (p = 0.04) as protective factors. TGF-β1 + 869CC genotype was less frequently found in “Mild progressors” compared to “Rapid progressors” [p = 0.019; OR (95%CI) = 0.19 (.05-.76)].


      The TGF-β1 +869CC genotype is associated with a lower risk of calcineurin inhibitor nephrotoxicity after heart transplant. This genetic susceptibility could enable a more personalized patient treatment.



      HT (heart transplant), CKD (chronic kidney disease), eGFR (estimated glomerular filtration rate), CNI (calcineurin inhibitors), TGF-β1 (transforming growth factor beta-1), RRT (renal replacement therapy), RT (renal transplantation), ORs (Odds ratios)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The Journal of Heart and Lung Transplantation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ojo AO
        • Held PJ
        • Port FK
        • et al.
        Chronic renal failure after transplantation of a nonrenal organ.
        N Engl J Med. 2003; 349: 931-940
      1. JHLT. 2019; 38: 1015-1066.

        • Tomas HL
        • Banner NR
        • Murphy CL
        • et al.
        Incidence, determinants, and outcome of chronic kidney disease after adult heart transplantation in the United Kingdom.
        Transplantation. 2012; 93: 1151-1157
        • Soderlund C.
        • Lofdahl E.
        • Nilsson J.
        • et al.
        Chronic kidney disease after heart transplantation: a single-centre retrospective study at Skane University Hospital in Lund 1988–2010.
        Transplant Int. 2016; 29: 529-539
        • Lindelöw B
        • Bergh CH
        • Herlitz H
        • Waagstein F.
        Predictors and evolution of renal function during 9 years following heart transplantation.
        J Am Soc Nephrol. 2000; 11: 951
        • Z AA
        • Abbas S
        • Moore E
        • Diallo O
        • Hauptman PJ
        • Bastani B
        The natural history of renal function following orthotopic heart transplant.
        Clin Transplant. 2005; 19: 683
        • Arora S
        • Andreassen A
        • Simonsen S
        • et al.
        Prognostic importance of renal function 1 year after Heart transplantation for all-cause and cardiac mortality and development of Allograft vasculopathy.
        Transplantation. 2007; 84: 149-154
        • Bloom RD
        • Reese PP.
        Chronic kidney disease after nonrenal solid-organ transplantation.
        J Am Soc Nephrol. 2007; 18: 3031-3041
        • Gijsen VM
        • Madadi P
        • Dubé MP
        • Hesselink DA
        • Koren G
        • de Wildt SN.
        Tacrolimus-induced nephrotoxicity and genetic variability: a review.
        Ann Transplant. 2012; 17: 111-121
        • Chapman JR.
        Chronic calcineurin inhibitor nephrotoxicity-lest we forget.
        Am J Transplant. 2011; 11: 693-697
        • Yoon HE
        • Yang CW.
        Established and newly proposed mechanisms of chronic cyclosporine nephropathy.
        Korean J Intern Med. 2009; 24: 81-92
        • Vahed SZ
        • Ardalan M
        • Samadi N
        • et al.
        Pharmacogenetics and drug induced nephrotoxicity in renal transplant recipients.
        BioImpat. 2015; 5: 45-54
        • Li B
        • Khanna A
        • Sharma V
        • Singh T
        • T Suthanthiran M
        • August P.
        TGF-β 1 DNA polymorphisms, protein levels and blood pressure.
        Hypertension. 1999; 33: 271-275
        • Li HY
        • Zhou T
        • Lin S
        • et al.
        Relationship between TGF-β1 + 869 T/C and + 915 G/C gene polymorphism and risk of acute rejection in renal transplantation recipients.
        BMC Med Genet. 2019; 20: 113
        • Bogacz A
        • Wolek M
        • Sieńko J
        • et al.
        Influence of TGFB1 and CTLA4 polymorphisms on calcineurin inhibitors dose and risk of acute rejection in renal transplantation.
        Sci Rep. 2021; 11: 17531
        • Baan CC
        • Balk AH
        • Holweg CT
        • et al.
        Renal failure after clinical heart transplantation is associated with the TGF-β 1 codon 10 gene polymorphism.
        J. Heart Lung Transplant. 2000; 19: 866-872
        • Van de Wetering J
        • Weimar CH
        • Balk AH
        • et al.
        The impact of transforming growth factor-beta1 gene polymorphism on end-stage renal failure after heart transplantation.
        Transplantation. 2006; 82: 1744-1748
        • Lacha J.
        • Hubacek JA.
        • Viklicky O.
        • Malek I.
        • Hutchinson I.
        • Vitko S.
        TGF-β1 gene polymorphism is a risk factor for renal dysfunction in heart transplant recipients.
        Transplant. Proc. 2001; 33: 1567-1569
        • Asleh R
        • Snipelisky D
        • Hathcock M
        • et al.
        Genomewide association study reveals novel genetic loci associated with change in renal function in heart transplant recipients.
        Clin. Transpl. 2018; 32: e13395
        • Oreschak K
        • Saba LM
        • Rafaels N
        • et al.
        Association between variants in calcineurin inhibitor pharmacokinetic and pharmacodynamic genes and renal dysfunction in adult heart transplant recipients.
        Front Genet. 2021; 12658983
        • Levey AS
        • Coresh J
        • Balk E
        • et al.
        National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.
        Ann Intern Med. 2003; 139 (-7): 137
        • Disease Kidney
        Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.
        Kidney Inter. 2013; 3: 1-150
        • Shaffi K
        • Uhlig K
        • Perrone RD
        • et al.
        Performance of creatinine-based eGFR estimating equations in solid-organ transplant recipients.
        Am J Kidney Dis. 2014; 63: 1007-1018
        • González-Vílchez F
        • Arizón JM
        • Segovia J
        • et al.
        Chronic renal dysfunction in maintenance heart transplant patients: the ICEBERG study.
        Transplant Proc. 2014; 46: 14-20
        • Delgado JF
        • Crespo-Leiro MG
        • Gómez-Sánchez MA
        • et al.
        Risk factors associated with moderate-to-severe renal dysfunction among heart transplant patients: results from the CAPRI study.
        Clin Transplant. 2010; 24: E194-E200
        • Wood NAP
        • Thomson SC
        • Smith RM
        • Bidwell JL.
        Identification of human TGF-b1 signal (leader) sequence polymorphisms by PCR-RFLP.
        J Immunological methods. 2000; 234: 117-122
        • Sanabria Ruiz-Colmenares MR
        • Pastor Jimeno JC
        • Garrote Adrados JA
        • Telleria Orriols JJ
        • Yugueros Fernández MI
        Cytokine gene polymorphisms in retinal detachment patients with and without proliferative vitreoretinopathy: a preliminary study.
        Acta Ophthalmol Scand. 2006; 84: 309-313
        • Uboldi de Capei MU
        • Dametto E
        • Fasano ME
        • Rendine S
        • Curtoni ES.
        Genotyping for cytokine polymorphisms: allele frequencies in the Italian population.
        Eur J Immunogenet. 2003; 30: 5-10
        • Cuenca AB
        • Citores MJ
        • De la Fuente S
        • et al.
        TT Genotype of transforming growth factor beta1 +869C/T is associated with the development of chronic kidney disease after liver transplantation.
        Transplant Proc. 2014; 46: 3108-3110
        • Park KH
        • Lo Han SG
        • Whang YM
        • et al.
        Single nucleotide polymorphisms of the TGFB1 gene and lung cancer risk in a Korean population.
        Cancer Genet Cytogenet. 2006; 169: 39-44